

STUDY ID: MID	-	
MUSIC Follow-U	D VISIT	

	VISIT DATE						
	Visit Date: (DD-MMM-YYYY)						
Vi	sit Timepoint: □ 3 months □ 6 months □ 9 months □ 12 months						
	DATIENT DETAILS						
CHI No.	CHI No. PATIENT DETAILS						
	CLINICAL ASSESSMENT						
Weight:kg							
Current smoking status: ☐ Yes ☐ No ☐ Ex -smoker If ex-smoker, when did they stop?							
Current active IBD symptoms: ☐ Yes ☐ No							
Description of symptoms:							
Physician's Global Assessment: ☐ Remission ☐ Mildly active ☐ Moderately active ☐ Severely active							
Comments:							

CLINICAL ASSESSMENT – CROHN'S DISEASE HBI – circle relevant options below

Total = sums of items on table + number of liquid stool/day <5 remission, 5-7 mild, 8-16 moderate, >16 severe

	0	1	2	3	4
Wellbeing	Very well	Slightly below par	Poor	Very Poor	Terrible
Abdo pain	None	Mild	Moderate	Severe	
Abdo mass	Nil	Dubious	Definite	Definite and tenderness	
Arthralgia	No	Yes			
Uveitis	No	Yes			
Erythema nodosum	No	Yes			
Aphthous ulcers	No	Yes			



STUDY ID: MID-	Subject Initials:
----------------	-------------------

MUSIC Follow-Up Visit

Pyoderma gangrenosum	No	Yes		
Anal fissure	No	Yes		
New fistula	No	Yes		
Abscess	No	Yes		
Liquid stools	No	Yes	If yes, no. of liquid stools a day:	
Total HBI score =				

CLINICAL ASSESSMENT – ULCERATIVE COLITIS SCCAI – circle relevant options below								
0 1 2 3 4								
Wellbeing	Very well	Slightly below par	Poor	Very Poor	Terribl e			
Bowel frequency (day)	0-3	4-6	7-9	>9				
Bowel frequency (night)	0	1-3	4-6					
Urgency of defecation	None	Hurry	Immediately (toilet nearby)	Incontinence				
Blood in stool	None	Trace	Occasionally frank (<50% of defecation)	Usually frank (>50% of defecation)				
Erythema nodosum	No	Yes						
Pyoderma gangrenosum	No	Yes						
Arthralgia	No	Yes						
Uveitis	No	Yes						
Total SCCAl score =								

CLINICAL ASSESSMENT PARTIAL MAYO SCORE – circle relevant options below						
0 1 2 3						
Stool frequency	Normal	1-2 more than normal	3-4 more than normal	≥5 more than normal		
Rectal bleeding	tal bleeding None Visible in <50% stools		Visible in >50% of stools	Frank blood		
Physician assessment Normal Mild Moderate Severe						
Total Partial Mayo score = (0-9) <2 remission, 2-4 mild, 5-7 moderate, >7 severe						



STUDY ID: MID-	Subject Initials:
----------------	-------------------

MUSIC Follow-Up Visit

A – 5-ASA B – Adalimumab C- Azathioprine D -Mercaptopurine E – Methotrexate Reason for stopping K – Steroid (enemas) L – Steroid (suppository) P – Methylpresnidolone Q – Prednisolone (oral) U – Budesonide (oral)							
R1: Primary non-response – did not respond to drug at all (specify below)							
R1: Primary non-response – did not respond to drug at all (specify below) R2: Secondary non-response – initially responded then lost response (specify below) R3: Treatment completed R4: Intolerance (specify below) R5: Adverse effect (specify below) R6: Confirmed immunogenicity R7: Other Specify:							
Frequency of Use							
F1: Once per day F2: Twice per day F3: Three times per day F4: Four times per day F5: Once per week							
F6: Fortnightly F7: Monthly F8: 6 weekly F9: 8 weekly F10: 3 monthly							
F11: Pro re nata F12: Alternate days F13: Six times per day F14: Five times per day F15: Other							
Drug brand							
B1:Adalimumab- Humira B2: Adalimumab- Amgevita B3: Adalimumab- Imraldi B4:Golimumab- Simponi							
B5: Infliximab- Remicade B6: Infliximab- Inflectra B7: Infliximab- Remsima B8: Infliximab- Flixabi							
B9: Mesalazine- Octasa B10: Mesalazine- Asacol B11: Mesalazine- Mezavant B12: Mesalazine- Pentasa							
B13: Mesalazine- Salofalk B14: Other							
CHANGE IN MAINTENANCE IBD MEDICATIONS							

	CHANGE IN MAINTENANCE IBD MEDICATIONS						
Has there	been a cha	nge in mainte	nance IBD medica	ation since the last			
		visit or	a plan to change t	hings at this visit? ☐ Yes ☐	No		
*this section is	for long-ter	m IBD therapy	. For steroid use pl	ease fill in the outcomes section	•		
Medicati	on 1	Dose	Frequency	Stop date:	Reason for stopping:		
Drug name	Brand	Dose	rrequericy	Stop date.	Reason for stopping.		
Medication 2		Dose	Frequency	Stop date:	Reason for stopping:		
Drug name	Brand	Dosc	Trequency	otop date.	reason for stopping.		
Medication 3 Dose Frequency Stop date: Reason for st			Reason for stopping:				
Drug name	Brand	Dose	Frequency	Stop date:	Reason for stopping.		



STUDY ID: MID- Subject Initials:	
MUSIC Follow-Up Visit	

NEW MEDICATIONS							
Medicati	on 1	Dose	Frequency			Start date:	
Drug name	Brand	2000	Trequency			Start date.	
]	
Medicati Drug name	on 2 Brand	Dose	Frequen	су		Start date:	
Drug Haille	Dianu					1-00-000	
Medicati		Dose	Frequen	ıcv		Start date:	
Drug name	Brand		110400				
]	
	SIGNII	FICANT D	OSE CH	ANGI	ES OF EXIST	TING THERAPY	
Drug na	me	Date of o	change	I	Description	Reason for change	
						☐ Drug monitoring guided – step up	
						☐ Drug monitoring guided – step down	
						☐ Secondary loss of response	
						☐ Planned reduction	
						☐ Other	
						☐ Drug monitoring guided – step up	
						☐ Drug monitoring guided – step down	
						☐ Secondary loss of response	
						☐ Planned reduction	
						☐ Other	
						☐ Drug monitoring guided – step up	
						☐ Drug monitoring guided – step down	
						☐ Secondary loss of response	
						☐ Planned reduction	
						☐ Other	
		CURF	RENT NO	N-IB	D MEDICATI	IONS	

CURRENT NON-IBD MEDICATIONS					
Has there been a significant change in non-IBD medication since the last visit? ☐ Yes ☐ No					
We are interested in	proton pump inhibitors, antibio	tics, NSAIDs and opiate use.			
Name	lame Date of change Description of change				



t Initials:	$\Box\Box$	
t I	nitials:	nitials: 🔲 📖

MUSIC Follow-Up Visit OUTCOMES

NEW STEROID USE						
Any new courses of oral steroids since the last visit? ☐ Yes ☐ No ☐ Ongoing since last visit						
Steroid Name	Dose	Frequency	Start d	date:	Stop date:	Reason for use:
						☐ Flare ☐ Other:
			Sti	II taken?	l □ Yes □ No (In NO	
Steroid Name	Dose	Frequency	Start d		Stop date:	Reason for use:
						□ Flare
			C+i	II takan?	│ □ Yes □ No (In NO	October:
			Su	II LAKEIT?	Lifes Lino (In No	, Complete Stop date)
Comments:						
		N	IEW FLA	RES		
Any new flares sin	ce the last	visit? 🗆 Ye	s □ No □	□ Ongoin	g since last visit	
			_		ief description of ma	
Approx. timeframe of	flare	Descript	ion	(community/inpatien ASA/diet	
					AOAIGIC	otios
Comments:						
	1.15.15		LICOPIE			
					MISSIONS	
Has the patient had an IBD-related hospital admission since the last visit? ☐ Yes ☐ No						
Date of Admission	Date of Di	scharge F	Reason for a	admissio	n	
			☐ Acute sever	re colitis		
			☐ Flare not meeting acute severe colitis criteria			
			☐ Perianal disease management eg abscess/I&D			kD .
			□ Surgery			
			☐ Admission for investigation (not meeting above criteria)			ve criteria)
		+	☐ Other:	100		
			☐ Acute seve		A	
			☐ Flare not meeting acute severe colitis criteria			
			☐ Perianal disease management eg abscess/I&D			kD
		L	☐ Surgery			



STUDY ID: MID- Subject Initials:	
MUSIC Follow-Up Visit	

		☐ Admission for investigation (not meeting above criteria) ☐ Other:				
Comments:						
			2115			
Han the west		IDD and a to discount		GERY	-1.::10 = 7.	
		n IBD-related surgic		ire since the la)
Date of Proced	lure	Type of Procedure)		Comments	
		☐ Colectomy				
		☐ Ileo-caecal/small bowel resection				
		☐ Other:				
	☐ Colectomy ☐ Ileo-caecal/small bowel resection					
	☐ Other:					
Comments:						
CHANGE IN MONTREAL CLASSIFICATION						
Has the patient had a change in Montreal classification since the last visit? ☐ Yes ☐ No						
						•
If yes, date of new Montreal classification:						
Crohn's Disease			Ulcerative Colitis			
☐ L1 ileal ☐ L2 colonic ☐ L3 ileocolonic ☐ +/- L4 upper GI disease		Extent	☐ E1 Proctitis only ☐ E2 Left-sided UC (d ☐ E3 Extensive UC (p	•		
Behaviour	□ B1 non-stricturing, non-penetrating □ B2 stricturing □ B3 penetrating □ +/- P perianal disease		Severity	□ S0 Remission□ S1 Mild UC□ S2 Moderate UC□ S3 Severe UC		



STUDY ID: MID-	Subject Initials:
	\

MUSIC Follow-Up Visit

SAMPLE COLLECTION				
Blood samples				
Were blood samples collected?	□ Yes	□ No	If yes, please record date and time collected below	
Serum 4.9ml (NHS)	□ Yes	□ No	Destination:	
EDTA 2.7ml (NHS)	□ Yes	□ No	Destination:	
EDTA 9/10ml #1	□ Yes	□ No	Destination:	
EDTA 9/10ml #2	□ Yes	□ No	Destination:	
PaxGene ccfDNA	□ Yes	□ No	Destination:	
PaxGene RNA	□ Yes	□ No	Destination:	
If no, reason not collected:				
Date Collected:			Time Collected: (24 Hour Clock)	
Stool samples				
Was a stool sample provided?	□ Yes	□ No	If yes, please record date and time collected below	
Faecal calprotectin	□ Yes	□ No	Destination:	
qFIT	□ Yes	□ No	Destination:	
OmniGut	□ Yes	□ No	Destination:	
If no, reason not collected:	□ Unabl	e to prod	uce 🗆 Other:	
Date Collected:]-[Time Collected: (24 Hour Clock)	
Saliva Sample				
Was a saliva sample collected?	□ Yes	□ No	If yes, please record date and time collected below	
If no, reason not collected:			Destination:	
Date Collected:]-[Time Collected: (24 Hour Clock)	
REMINDERS				
Has patient completed CUCQ32 questionnaire? ☐ Yes ☐ No				
Has the patient been provided with sample kits to take home? ☐ Yes ☐ No ☐ N/A				
Have the patient's medical records been updated following this visit? ☐ Yes ☐ No				